Cullinan advances multiple myeloma drug CLN-619 to a Phase I study

01 Mar 2024
www.pharmaceutical-technology.com
Cullinan advances multiple myeloma drug CLN-619 to a Phase I study
Preview
Source: Pharmaceutical Technology
The company plans for a Phase I dose-escalation and dose-expansion study with CLN-619. Credits: Lightspring/Shutterstock.com
Cullinan Oncology is gearing up to advance one of its lead drugs CLN-619 into a Phase I clinical study for multiple myeloma following US Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND).
According to the 1 March press release, the planned Phase I study will comprise of a dose escalation and dose expansion phase testing CLN-619 as a potential treatment for relapsed or refractory multiple myeloma.
CLN-619, an intravenously administered anti-MICA humanized IgG1 monoclonal antibody, is designed to inhibit MHC class I polypeptide related sequence A (MICA) and MHC class I polypeptide related sequence B (MICB) to induce activation of natural killer group 2D (NKG2D) receptors. In engaging these receptors, CLN-619 is hypothesised to promote the cytotoxicity and lysis of NK-mediated tumour cells. As per Cullinan CMO Dr. Jeffrey Jones, CLN-619 is capable of restoring MICA/B expression on tumor cells and enabling immune recognition.
The Phase I study will be the first MICA/B antibody clinical study in hematologic malignancies, according to the company.
The Cambridge, Massachusetts-based biotech is also evaluating CLN-619 as a monotherapy and in combination with MSD’s Keytruda (pembrolizumab) in a Phase I study (NCT05117476) for advanced solid tumours. Cullinan expects “updated” clinical data in Q2 2024.
See Also:Market cap upturn for top 20 biopharma companies with obesity drug successes in 2023
Cullinan advances multiple myeloma drug CLN-619 to a Phase I study
Preview
Source: Pharmaceutical Technology
Lutris wins FDA orphan drug tag for EGFR inhibitorEGFR inhibitor-induced rashEGFR inhibitor-induced rash candidate
Cullinan advances multiple myeloma drug CLN-619 to a Phase I study
Preview
Source: Pharmaceutical Technology
Cullinan is far from being the only company playing in the multiple myeloma space. Last month, Starton Therapeutics announced that it had activated another site for its Phase Ib STAR-LLD study (NCT06087653) that is evaluating a continuous subcutaneous low-dose lenalidomide in combination with dexamethasone and Takeda’s Velcade (bortezomib).
Also in February, GSK published interim results from the Phase III DREAMM-7 study assessing a combination treatment comprised of its antibody drug conjugate Blenrep (belantamab mafodotin) alongside bortezomib and dexamethasone (BorDex) in a head-to-head comparison against a combination with Janssen Oncology’s Darzalex (daratumumab). The study reported that it found significant improvements in progression free survival (PFS) in patients with relapsed or refractory multiple myeloma.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.